Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U54CA156732 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
The overall goal of this study is to qualitatively explore how behavioral, cultural, psychosocial, and economic barriers and facilitators affect the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
A qualitative study that will use interviews to gain an in depth understanding of factors affecting the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Quality Of Life | This study uses qualitative research methods, specifically semi-structured interviews.
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Phone interview | Other | Collecting clinical and socio-demographic information. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Decision-making around endocrine therapy in young women with HR+ breast cancer. | Open ended questions | 3 months-3 years post active treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Barriers and challenges to endocrine therapy adherence | Open ended questions | 3 months-3 years post active treatment |
| Social support | Open ended questions |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Women of all races
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rachel A Freedman, MD, MPH | Dana-Farber Cancer Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 months-3 years post active treatment |
| Health behaviors | Open ended questions | 3 months-3 years post active treatment |
| Endocrine therapy adherence intervention preferences | Open ended questions | 3 months-3 years post active treatment |
| Health literacy | Brief Health Literacy Screener (Chew items) | 3 months-3 years post active treatment |
| Menopausal symptoms | BCPT Symptom Checklist | 3 months-3 years post active treatment |
| D017437 |
| Skin and Connective Tissue Diseases |